While SAB Biotherapeutics beat EPS estimates, which could be seen as a positive sign, the substantial decrease in sales year-over-year is likely to raise concerns among investors about the company's revenue growth and future profitability. The mixed results present both positive and negative aspects, leading to a neutral short-term impact on the stock price.